Generic drug companies fill more than 90% of all U.S. prescriptions and have saved the healthcare system an estimated $3.1 […]
The Generic Drug Maker’s Escape Route: How 505(b)(2) Turns Commodities into Cash Cows Read Post »
Section 1: The Regulatory Trinity: Anatomy of the Three Small-Molecule Pathways Why the Categorization Matters More Than Most Teams Think
The 505(b)(2) Pathway: Unlocking a Hybrid Strategy for Drug Innovation Read Post »
1. What Pharmaceutical Portfolio Management Actually Is (and What Most Teams Get Wrong) Pharmaceutical portfolio management is the discipline of
I. Executive Summary Follow-on pharmaceutical innovations represent a critical, often underestimated, dimension of medical progress. These advancements, which build upon
Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection Read Post »
A technical deep dive for pharma IP teams, R&D leads, and institutional investors on the world’s most consequential pharmaceutical patent
A comparative deep dive for pharma and biotech IP teams, R&D leads, and institutional investors navigating the two most consequential
The Economic Imperative of Time In the pharmaceutical sector, time is a tangible asset with a valuation that often exceeds
Executive Summary The United States pharmaceutical market is characterized by a complex and often opaque pricing structure, leading to a
1. The Pricing Crisis in Numbers The United States spends more per capita on prescription drugs than any other OECD
Precision Medicine Drug Pricing: The Complete IP, Patent, and Market Access Playbook Read Post »
Get fresh news and insights, drug patent expirations & more…
